Investor Relations 2021

Key Business Performance ✓ Completed launching in more than 70% of EU market including EU5 countries by 1Q21 RemsimaⓇ SC ✓ Aiming to expand the market entry by launching other global markets such as Canada and Australia this year Current Status Launching plan in Canada & Australia Launched to more than 70% of the entire EU Market Launched Completed launching in France, Spain, and Italy in 1021 H TNF-α Expand target market Planning to launch to other global markets $1.8bn $317mn Market Size Aiming to expand regions by launching in other global markets such as Canada and Australia Approval Jan. 2021 Dec. 2020 Direct Induction Received positive CHMP opinion for direct use of Subcutaneous therapy without IV loading with RA patients (for Rheumatoid Arthritis) - The Committee for Medicinal Products for Human USE(CHMP) of the European Medicines Agency(EMA) has recommended RemsimaⓇ SC for direct use of subcutaneous therapy without IV loading in adults with rheumatoid arthritis (RA) Launching Timeline Note: market size is as of 2020 Source: IQVIA 2Q21 3Q21 Investor Relations 2021 11

View entire presentation